Shares in Oxford BioMedica fell 15% today despite a recent positive half-year trading update.
In early August, the MedTech said H1 2026 revenues had grown 9% to approximately £80 million.
That followed the rejection of several takeover offers from Swedish private equity firm EQT for the cell and gene therapy developer.
However Oxford Biomedica, founded in 1995 and listed in London for 30 years, seems open to a take-private deal from other PE houses which may be more aligned with its business, CEO Frank Mathias said recently.
The FTSE 250 firm’s share price reached 913 pence in January amid the early EQT takeover rumours, but has since fallen way back. It is down more than 30% in the year to date and currently sits at 447p, giving it a market cap of £541 million.
Oxford BioMedica manufactured COVID vaccines on behalf of pharma giant AstraZeneca and now focuses on autoimmune disorders and cancer therapies.